Abstract:UNLABELLED Adjuvant intravesical bacillus Calmette- Guérin (BCG) therapy is the standard conservative adjuvant treatment and the most effective regimen for patients with high-risk non-muscle-invasive bladder cancer (NMIBC). The term "BCG failure" is generally used to refer to recurrence or progression following BCG therapy, as experienced by many patients. However, the term has been defined inconsistently, and several studies have indicated that patients with a particular pattern of BCG failure have a worse prognosis. There are many different treatment options for patients who experience BCG failure. OBJECTIVE To summarize the different current definitions of BCG failure and the present treatment options available for patients with high-risk NMIBC who experience BCG failure. EVIDENCE SYNTHESIS Overall, the failure rate in response to BCG is about 40-50%. Most guidelines recommend that patients failing BCG should be offered radical cystectomy (RC). The significant potential for progression specific to high-risk NMIBC leads some clinicians to argue that immediate RC should be considered the preferred first-line treatment in high-risk patients, bearing in mind that it achieves a long-term survival rate in excess of 90% with ongoing improvements in morbidity. While other salvage intravesical treatments have to be considered oncologically inferior to RC, several therapies are now available if the patient is unfit to undergo RC or if bladder preservation is the objective, and some agents have shown promise in the context of BCG failure. CONCLUSIONS The definition, prediction, and treatment of BCG failure remain topics of debate. Patients with BCG failure need carefully selected, individualized therapy in experienced hands. Stratification of patients with BCG failure into groups can identify those with a better or worse prognosis. RC should be the selected option if a patient experiences BCG failure, but several promising intravesical salvage options are available for those cases in which the patient is unfit for surgery or bladder preservation is preferred. Currently data are still inadequate to allow formulation of definitive recommendations, and larger and higher quality studies of salvage intravesical therapies are urgently required.

Identification and Releasing Characteristics of Β-Cyclodextrin–phenylethanoid Glycosides Inclusion Complex

Preparation and Properties of Ginger Essential Oil Β-Cyclodextrin/chitosan Inclusion Complexes

Preparation, release and physicochemical characterisation of ethyl butyrate and hexanal inclusion complexes with β- and γ-cyclodextrin

Failure of Bacillus Calmette-Guérin therapy in non-muscle-invasive bladder cancer: Definition and treatment options.

Preparation and Physicochemical Properties of Glipizide-β-Cyclodextrin Inclusion Complex

Molecular dynamics simulations and theoretical calculations of cyclodextrin-polydatin inclusion complexes

Inclusion complexes of β-cyclodextrin with isomeric ester aroma compounds: Preparation, characterization, mechanism study, and controlled release

Preparation of inclusion complex of daidzein and hydropropyl-β- cyclodextrin

Molecular mechanics study of β-cyclodextrin 6-O-monobenzoate inclusion complexes

Experimental and Theoretical Studies on the Inclusion Complexation of β-Cyclodextrin with Phenothiazine Derivatives

Inclusion complexation of β-CD with phenothiazine and N-alkylphenothiazine derivatives

Studies on Molecular Recongnition of (A)-Cyclodextrin with Diphenyl Compounds

Unveiling the Intricate Supramolecular Chemistry of γ-Cyclodextrin-Epigallocatechin Gallate Inclusion Complexes

Investigation the complex of 2,6-di-O-methyl-β-cyclodextrin and chlorzoxazone: preparation, characterization, dissolution, and cytotoxicity

Inclusion complexes of <img src="/fulltext-image.asp?format=htmlnonpaginated&src=EU41546R84R73825_html\10847_2007_9357_Article_IEq1.gif" border="0" alt="$$\hbox{cholesteryl-(}\varepsilon\hbox{-caprolactone})_{\overline{10}}$$" /> functionalized polymer with γ-cyclodextrin

Synthesis, characterization, molecular modeling, binding energies of β-cyclodextrin-inclusion complexes of quercetin: Modification of photo physical behavior upon β-CD complexation

Identification of Irisquinone Hydroxypropyl-Β-cyclodextrin Inclusion Compound and Its Thermodynamic Stability

Inclusion Complexation of Flavonoids with Cyclodextrin: Molecular Docking and Experimental Study

Characterization, molecular dynamics, and encapsulation ability of β-cyclodextrin polymers crosslinked by polyethylene glycol

Molecular simulation investigation ofα-cyclodextrin inclusion complex with 2-phenylethyl alcohol

Interaction Between Β-Cyclodextrin and 1,10-Phenanthroline: Uncommon 2:3 Inclusion Complex in the Solid State